{"id":1251,"date":"2026-04-05T14:56:45","date_gmt":"2026-04-05T14:56:45","guid":{"rendered":"https:\/\/www.curedm.co.uk\/?page_id=1251"},"modified":"2026-04-05T14:58:23","modified_gmt":"2026-04-05T14:58:23","slug":"amo-pharma","status":"publish","type":"page","link":"https:\/\/www.curedm.co.uk\/?page_id=1251","title":{"rendered":"AMO Pharma"},"content":{"rendered":"\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<p>AM0-02 is a clinical stage investigational medicine for the treatment of the most severe form of DM: congenital myotonic dystrophy. <\/p>\n\n\n\n<p>In cellular and animal models of DM1 as well as in muscle biopsies from patients, activity of glycogen synthase kinase 3 beta (GSK3\u00df) has been shown to increase. AMO-02 is an inhibitor that has been shown to normalise levels of GSK3\u00df in transgenic models and in ex vivo tissue samples in patients with DM1 and to reduce levels of the mRNA that is pathogenic for DM1.<\/p>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><a href=\"https:\/\/www.reachcdm.com\/\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"681\" height=\"152\" src=\"https:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/AMO-REACH-CDM.jpg\" alt=\"\" class=\"wp-image-1252 size-full\" srcset=\"https:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/AMO-REACH-CDM.jpg 681w, https:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/AMO-REACH-CDM-300x67.jpg 300w\" sizes=\"auto, (max-width: 681px) 100vw, 681px\" \/><\/a><\/figure><div class=\"wp-block-media-text__content\">\n<p>Learn more about the current study: REACH CDM <\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/www.amo-pharma.com\" target=\"_blank\" rel=\" noreferrer noopener\"><img decoding=\"async\" src=\"http:\/\/www.curedm.co.uk\/wp-content\/uploads\/2026\/04\/AMO-banner.jpg\" alt=\"\" class=\"wp-image-1248\"\/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\"><strong>Press releases and updates<\/strong><\/h2>\n\n\n\n<p>September 15th, 2025: <a href=\"https:\/\/www.amo-pharma.com\/news\/Press_Release_250915.htm\" target=\"_blank\" rel=\"noreferrer noopener\">AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AM0-02 is a clinical stage investigational medicine for the treatment of the most severe form of DM: congenital myotonic dystrophy. In cellular and animal models of DM1 as well as in muscle biopsies from patients, activity of glycogen synthase kinase 3 beta (GSK3\u00df) has been shown to increase. AMO-02 is an inhibitor that has been [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1229,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1251","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1251"}],"version-history":[{"count":1,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1251\/revisions"}],"predecessor-version":[{"id":1253,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1251\/revisions\/1253"}],"up":[{"embeddable":true,"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/1229"}],"wp:attachment":[{"href":"https:\/\/www.curedm.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}